In recent years, adjuvant therapy for colorectal cancer has advanced considerably.
This article reviews these advances and provides an update of the most recent and ongoing trials.
In 1990, adjuvant therapy became the « standard of care » for patients with Stage III colon cancer (Dukes C) in the United States.
Recent clinical trial data indicate that adjuvant treatment may also be effective in patients with Stage II (Dukes B2) colon cancer.
The combination of 5-fluorouracil plus leucovorin may slightly improve survival (5-10 percent) compared with the standard 5-fluorouracil plus levamisole combination.
The three-drug regimen (5-fluorouracil plus levamisole plus leucovorin) is more toxic, with no superior effect on survival.
Intraportal chemotherapy, although it may significantly improve patient survival, does not decrease the frequency of liver metastases.
However, it is still a promising form of adjuvant therapy owing to its short treatment period and relatively equivalent effects in survival compared with that of systemic therapy.
For patients with Stage II or Stage III rectal cancer, postoperative systemic 5-fluorouracil plus radiation therapy plus protracted venous 5-fluorouracil infusion is the most effective postoperative adjuvant regimen. (...)
Mots-clés Pascal : Carcinome, Côlon, Rectum, Traitement adjuvant, Mise au point, Critère décision, Efficacité traitement, Classification, Revue bibliographique, Pharmacocinétique, Article synthèse, Homme, Indication, Tumeur maligne, Appareil digestif pathologie, Intestin pathologie, Côlon pathologie, Rectum pathologie, Anticancéreux, Pharmacologie
Mots-clés Pascal anglais : Carcinoma, Colon, Rectum, Adjuvant treatment, Perfecting, Decision criterion, Treatment efficiency, Classification, Bibliographic review, Pharmacokinetics, Review, Human, Indication, Malignant tumor, Digestive diseases, Intestinal disease, Colonic disease, Rectal disease, Antineoplastic agent, Pharmacology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0484886
Code Inist : 002B02R04. Création : 03/02/1998.